Journal of Neuro-Oncology最新文献

{"title":"DTI fiber-tracking parameters adjacent to gliomas: the role of tract irregularity value in operative planning, resection, and outcome.","authors":"Daniele Armocida, Andrea Bianconi, Giuseppa Zancana, Tingting Jiang, Alessandro Pesce, Fulvio Tartara, Diego Garbossa, Maurizio Salvati, Antonio Santoro, Carlo Serra, Alessandro Frati","doi":"10.1007/s11060-024-04848-3","DOIUrl":"10.1007/s11060-024-04848-3","url":null,"abstract":"<p><strong>Purpose: </strong>The goal of glioma surgery is maximal tumor resection associated with minimal post-operative morbidity. Diffusion tensor imaging-tractography/fiber tracking (DTI-FT) is a valuable white-matter (WM) visualization tool for diagnosis and surgical planning. Still, it assumes a descriptive role since the main DTI metrics and parameters showed several limitations in clinical use. New applications and quantitative measurements were recently applied to describe WM architecture that surround the tumor area. The brain adjacent tumor area (BAT) is defined as the region adjacent to the gross tumor volume, which contains signal abnormalities on T2-weighted or FLAIR sequences. The DTI-FT analysis of the BAT can be adopted as predictive values and a guide for safe tumor resection.</p><p><strong>Methods: </strong>This is an observational prospective study on an extensive series of glioma patients who performed magnetic resonance imaging (MRI) with pre-operative DTI-FT analyzed on the BAT by two different software. We examined DTI parameters of Fractional anisotropy (FA mean, min-max), Mean diffusivity (MD), and the shape-metric \"tract irregularity\" (TI) grade, comparing it with the surgical series' clinical, radiological, and outcome data.</p><p><strong>Results: </strong>The population consisted of 118 patients, with a mean age of 60.6 years. 82 patients suffering from high-grade gliomas (69.5%), and 36 from low-grade gliomas (30.5%). A significant inverse relationship exists between the FA mean value and grading (p = 0.001). The relationship appears directly proportional regarding MD values (p = 0.003) and TI values (p = 0.005). FA mean and MD values are susceptible to significant variations with tumor and edema volume (p = 0.05). TI showed an independent relationship with grading regardless of tumor radiological features and dimensions, with a direct relationship with grading, ki67% (p = 0,05), PFS (p < 0.001), and EOR (p < 0.01).</p><p><strong>Conclusion: </strong>FA, MD, and TI are useful predictive measures of the clinical behavior of glioma, and TI could be helpful for tumor grading identification and surgical planning.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"241-252"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11685273/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142467846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of life after stereotactic radiosurgery for brain metastasis: an assessment from a prospective national registry.","authors":"Duy Q Pham, Darrah E Sheehan, Kimball A Sheehan, Konstantinos Katsos, Camilo E Fadul","doi":"10.1007/s11060-024-04854-5","DOIUrl":"10.1007/s11060-024-04854-5","url":null,"abstract":"<p><strong>Purpose: </strong>Stereotactic radiosurgery (SRS) is frequently used in the management of brain metastasis patients. However, there is an urgent need to evaluate post-treatment outcomes and quality of life metrics for patients undergoing SRS for brain metastases.</p><p><strong>Methods: </strong>The NeuroPoint Alliance (NPA) SRS Quality Registry conducted prospective enrollment of patients undergoing SRS from 2017 to 2024. Patients with brain metastases from lung cancer, breast cancer, and melanoma were included in the analysis. Outcomes of interest included quality of life metrics, as captured by the five-dimension Euro-QOL (EQ-5D) at 6-12 months and last record follow-up, overall survival, local progression, out-of-field progression, and overall intracranial progression.</p><p><strong>Results: </strong>522 patients comprised our analytic cohort, and 315 patients had available EQ-5D data at the time of SRS and final follow-up. 264 (47.8%), 197 (35.7%), and 91 (16.5%) patients had 1, 2-4, and 5-14 lesions pre-SRS, respectively. The median overall survival time from diagnosis was 27.3 months. The median time-to-local progression was not reached. At final follow-up, 107 (34.0%) patients had improvement, 51 (16.2%) patients had stable, and 113 patients (35.9%) had worsening EQ-5D scores when compared to baseline. For 44 (13.9%) patients mixed responses across the EQ-5D indices were reported. Linear regression analysis showed that male sex, smoking status, primary tumor type, time-to-overall progression, cumulative intracranial tumor volume (CITV), and baseline EQ-5D were statistically significantly associated with EQ-5D single index at the final follow-up.</p><p><strong>Conclusion: </strong>Real-world data from the SRS NPA Registry demonstrated that most patients with brain metastasis had no change or improvement in quality of life after SRS. Baseline EQ-5D was predictive of EQ-5D single index at final follow-up, and, as such, EQ-5D at baseline would be a valuable assessment measure for brain metastasis patients undergoing SRS.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"383-391"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11695642/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142467850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Impact of instrumentation material on local recurrence: a case-matched series using carbon fiber-PEEK vs. titanium.","authors":"Jacob Ward, Mark Damante, Seth Wilson, Vicente Coelho, Dominic Franceschelli, Ahmed Nader Elguindy, Evan M Thomas, Simeng Zhu, Dukagjin Blakaj, Sasha Beyer, Raju Raval, Raj Singh, David S Xu, J Bradley Elder, Joshua D Palmer, Vikram B Chakravarthy","doi":"10.1007/s11060-024-04860-7","DOIUrl":"10.1007/s11060-024-04860-7","url":null,"abstract":"","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"163"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11685251/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142604425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Study of prediction model for high-grade meningioma using fractal geometry combined with radiological features.","authors":"Zhaoxin Fan, Aili Gao, Jie Zhang, Xiangyi Meng, Qunxin Yin, Yongze Shen, Renjie Hu, Shang Gao, Hongge Yang, Yingqi Xu, Hongsheng Liang","doi":"10.1007/s11060-024-04867-0","DOIUrl":"10.1007/s11060-024-04867-0","url":null,"abstract":"<p><strong>Purpose: </strong>To establish a prediction model combining fractal geometry and radiological features, which consider the complexity of tumour morphology advancing beyond the limitations of previous models.</p><p><strong>Methods: </strong>A total of 227 patients at the First Affiliated Hospital of Harbin Medical University from July 2021 to November 2023 were included. Fractal geometry was calculated and the radiomics features were extracted from regions of interest (ROIs). Weighted Gene Co-Expression Network Analysis (WGCNA) was employed for preliminary screening to identify those that were significantly associated with high-grade meningioma. In the training cohort, the least absolute shrinkage and selection operator (LASSO) regression was employed for further screening the radiomics features. Area under curve (AUC) was to evaluate models' performance.</p><p><strong>Results: </strong>In entire patient cohort, low-grade meningiomas had significantly lower fractal dimensions (P = 0.01), while high-grade meningiomas had higher lacunarity (P = 0.049). Fractal dimension (OR 6.8, 95% CI 1.49-36.51, P = 0.017), lacunarity (OR 3.7, 95% CI 1.36-11.75, P = 0.014), and Rscore (OR 2.8, 95% CI 1.55-5.75, P = 0.002) were independent risk factors for high-grade meningiomas. The final results demonstrated that the \"fractal geometry + radiological features (semantic features + radiomics features)\" model exhibited the most optimal performance in predicting high-grade meningioma, with an AUC of 0.854 in the training cohort and 0.757 in the validation cohort.</p><p><strong>Conclusion: </strong>Significant differences in fractal dimension and lacunarity exist between high-grade and low-grade meningiomas, which can be potential predictive factors. The developed predictive model demonstrated good performance in predicting high-grade meningiomas.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"431-442"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142576109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combinatorial therapies for epigenetic, immunotherapeutic, and genetic targeting of chordoma.","authors":"Christian Godinez, Beatrice Campilan, Christian Schroeder, Jonathan Arditi, Madison J Michles, Benjamín Córdova Herrera, Kaylee Gallagher, Tati-Anna Robinson, Tyler Owens, Ziya L Gokaslan, Patricia Sullivan, Margot Martinez-Moreno","doi":"10.1007/s11060-024-04920-y","DOIUrl":"https://doi.org/10.1007/s11060-024-04920-y","url":null,"abstract":"<p><strong>Purpose: </strong>Chordoma, a rare malignancy of the axial skeleton and skull base, presents significant therapeutic challenges due to the high rates of tumor recurrence and resistance. While surgical resection and radiation therapy remain the gold standard of treatment, the lack of additional treatment options necessitates the exploration of novel therapies. Combinatorial therapies hold significant potential in shaping patient prognosis. By targeting the immunotherapeutic, epigenetic, and genetic landscapes of chordoma, these methods enable the more effective and personalized management of the diverse molecular mechanisms driving chordoma growth and resistance.</p><p><strong>Methods: </strong>To elucidate such potential, we conducted a literature review of all published articles on the usage of immunotherapeutic, epigenetic, and genetic approaches for chordoma treatment from 2014 to 2024.</p><p><strong>Results: </strong>Eighty-one papers were excluded based on our inclusion criteria. From the remaining thirty-nine publications, we found evidence supporting the efficacy of immune checkpoint inhibitors (ICIs), chimeric antigen receptor (CAR) T-cell therapies, and monoclonal antibodies; the roles of DNA methylation patterns, histone modification pathways, and miRNA regulation; and the contribution of cancer stem-like cells (CSCs) to chordoma progression.</p><p><strong>Conclusion: </strong>Our findings underscore the importance of a multidirectional approach in chordoma treatment throughout the disease progression to reduce morbidity and improve patient outcomes despite the heterogeneity of chordoma.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142909764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cerebral spinal fluid analyses and therapeutic implications for leptomeningeal metastatic disease.","authors":"Jie Wei Zhu, Megan Shum, Maleeha A Qazi, Arjun Sahgal, Sunit Das, Matthew Dankner, Ines Menjak, Mary Jane Lim-Fat, Katarzyna J Jerzak","doi":"10.1007/s11060-024-04902-0","DOIUrl":"https://doi.org/10.1007/s11060-024-04902-0","url":null,"abstract":"<p><strong>Purpose: </strong>To review applications of cerebral spinal fluid (CSF) biomarkers for the diagnosis, monitoring and treatment of leptomeningeal metastatic disease (LMD) among patients with metastatic solid tumors.</p><p><strong>Methods: </strong>A narrative review identified original research related to CSF biomarkers among patients with metastatic solid tumors and LMD. Pre-clinical research (e.g. studies conducted in animal models) was not included. A descriptive analysis of literature was undertaken, with a focus on clinical applications related to the diagnosis, monitoring and treatment of LMD.</p><p><strong>Results: </strong>The low cellularity of CSF in comparison to plasma is an advantage for liquid biopsy, given that circulating tumor DNA (ctDNA) is not significantly diluted by genomic DNA from non-cancer cells. This results in higher variant allelic frequencies and increased sensitivity in detecting ctDNA compared to plasma. However, the clinical significance of positive ctDNA and/or circulating tumor cells (CTCs) in the CSF, particularly in the absence of other signs of LMD (either clinical and/or radiological), remains unclear. While the use of CSF liquid biopsy to monitor treatment response is promising, this approach requires prospective validation using larger sample sizes prior to adoption in routine clinical care. Discovery efforts involving proteomics and metabolomics have potential to identify proteins involved in the regulation of energy metabolism, vasculature, and inflammation in LMD, which in turn, may offer insights into novel treatment approaches.</p><p><strong>Conclusion: </strong>CSF liquid biopsy should be incorporated in prospective studies for patients with LMD to validate promising diagnostic and/or predictive biomarkers of treatment response, as well as new therapeutic targets.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142864542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment-induced ripple effect: a systematic review exploring the abscopal phenomenon in Glioblastoma multiforme.","authors":"Ali Haider Bangash, Prabhat Poudel, Khalid M Alshuqayfi, Mudassir Ahmed, Oluwaseun O Akinduro, Walid Ibn Essayed, Afshin Salehi, Rafael De la Garza Ramos, Reza Yassari, Harminder Singh, Jason P Sheehan, Yoshua Esquenazi","doi":"10.1007/s11060-024-04912-y","DOIUrl":"https://doi.org/10.1007/s11060-024-04912-y","url":null,"abstract":"<p><strong>Purpose: </strong>This systematic review aimed to collate and synthesize the available literature on the abscopal effect in Glioblastoma multiforme (GBM) neoplasms, focusing on the reported biochemical mechanisms driving the abscopal effect.</p><p><strong>Methods: </strong>A systematic search was conducted in PubMed, Cochrane Database of Systematic Reviews, and Epistemonikos from inception to May 1, 2023. Studies exploring the abscopal effect in GBM were included. The Clinical Relevance Assessment of Animal Preclinical research (RAA) tool was used to assess methodological quality of preclinical studies. Data on preclinical models, biochemical mechanisms, and outcomes were extracted and synthesized systrmatically.</p><p><strong>Results: </strong>Out of a total of 7 studies, five preclinical studies met the inclusion criteria. The studies utilized various in vivo mouse models, including bilateral tumor models and immunohumanized mice. Key biochemical mechanisms identified included immunogenic cell death, danger-associated molecular pattern release, macrophage activation, and enhanced T cell responses. Combinatorial approaches involving oncolytic virotherapy, nanoparticle-based treatments, radiation therapy, and immune checkpoint inhibitors showed promise in inducing abscopal effects. Significant tumor growth inhibition and improved survival were reported in treated animals. However, the RAA analysis highlighted concerns regarding research transparency and internal validity across studies.</p><p><strong>Conclusions: </strong>This systematic review highlighted the potential of the abscopal effect in GBM, demonstrating its ability to enhance anti-tumor immune responses both locally and systemically. The synergistic effects of combinatorial approaches showed promise for improving outcomes. However, the low methodological quality of existing studies underscored the need for more rigorous preclinical research. Future studies should focus on improving research transparency, exploring the abscopal effect in other primary CNS neoplasms, and translating these findings into clinical trials to assess safety and efficacy in humans.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142854465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Precision radiotherapy with molecular-profiling of CNS tumours.","authors":"Deepak Dinakaran, Daniel Moore-Palhares, Fan Yang, Jordan B Hill","doi":"10.1007/s11060-024-04911-z","DOIUrl":"https://doi.org/10.1007/s11060-024-04911-z","url":null,"abstract":"<p><p>Diagnoses of CNS malignancies in the primary and metastatic setting have significantly advanced in the last decade with the advent of molecular pathology. Using a combination of immunohistochemistry, next-generation sequencing, and methylation profiling integrated with traditional histopathology, patient prognosis and disease characteristics can be understood to a much greater extent. This has recently manifested in predicting response to targeted drug therapies that are redefining management practices of CNS tumours. Radiotherapy, along with surgery, still remains an integral part of treating the majority of CNS tumours. However, the rapid advances in CNS molecular diagnostics have not yet been effectively translated into improving CNS radiotherapy. We explore several promising strategies under development to integrate molecular oncology into radiotherapy, and explore future directions that can serve to use molecular diagnostics to personalize radiotherapy. Evolving the management of CNS tumours with molecular profiling will be integral to supporting the future of precision radiotherapy.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142854418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical progress in the development of CAR T cells to treat malignant glioma.","authors":"Eric P Grewal, Brian V Nahed, Bob S Carter, Elizabeth R Gerstner, William T Curry, Marcela V Maus, Bryan D Choi","doi":"10.1007/s11060-024-04909-7","DOIUrl":"https://doi.org/10.1007/s11060-024-04909-7","url":null,"abstract":"<p><strong>Context: </strong>Chimeric antigen receptor (CAR) T cell therapy is an exciting modality of immunotherapy that has revolutionized the treatment of hematologic malignancies. However, translating this success to malignant gliomas such as glioblastoma (GBM) and diffuse midline glioma (DMG) remains a formidable challenge due to multiple biologic, anatomic, and immunologic factors. Despite these hurdles, a number of clinical trials deployed over the last decade have increased optimism for the potential of CAR T cell therapy in glioma treatment.</p><p><strong>Evidence synthesis: </strong>We highlight historical and ongoing clinical trials of CAR T cell therapy in glioma, with a focus on key tumor-associated antigens such as IL-13Rα2, HER2, EGFR, EGFRvIII, EphA2, GD2, and B7-H3. Early studies established proof-of-concept for antigen-specific CAR T cell targeting, yet immune evasion mechanisms such as antigen downregulation and limited CAR T cell persistence remain significant obstacles. Recent approaches, including multiantigen targeting, alternative cell sources, and innovations in delivery routes offer promising strategies to overcome these challenges.</p><p><strong>Conclusions: </strong>The rapid evolution of investigational CAR T cell therapies portends great potential for the future of glioma treatment. Future studies will need to refine antigen targeting strategies, optimize CAR T cell persistence, and integrate combinatorial approaches to fully harness the therapeutic potential of this modality and improve the therapeutic window against brain tumors.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142854414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Developmental gene expression in skull-base chordomas and chondrosarcomas.","authors":"Cas Vanderheijden, Youssef Yakkioui, Thomas Vaessen, Remco Santegoeds, Yasin Temel, Govert Hoogland, Koos Hovinga","doi":"10.1007/s11060-024-04913-x","DOIUrl":"https://doi.org/10.1007/s11060-024-04913-x","url":null,"abstract":"<p><strong>Purpose: </strong> Chordomas are malignant tumors of the axial spine and skull base, and they are notorious for their poor treatment response. Differentiating these tumors from comparatively less malignant chondrosarcomas is crucial for treatment and prognostication. Both tumor types differ in their developmental origin. Chordomas are considered to be derived from notochordal remnants and chondrosarcomas from mesenchymal cells. Here, we evaluated the differential expression of developmental transcription factors in these skull base tumors.</p><p><strong>Methods: </strong> Histopathologically-confirmed tumor biopsies were obtained from 12 chordoma and 7 chondrosarcoma patients. Following RNA extraction, samples were submitted to real-time quantitative PCR (RT-qPCR) for the evaluation of 32 evolutionary conserved genes that are known to associate with notochord, mesoderm, and axial spine development. Gene expression levels were normalized to housekeeping genes ACTB and RS27a.</p><p><strong>Results: </strong> Fifteen genes were either exclusively expressed (n = 12) or overexpressed (n = 3; 2.21-4.43 fold increase) in chordoma, compared to chondrosarcoma. Brachyury and CD24 were highly and exclusively expressed in chordoma. Other novel genes exclusive to chordomas included chordin, HOXA5 and ACAN. Vice versa, ten genes were either exclusively expressed (n = 2) or overexpressed (n = 8; 0.01-0.66 fold increase) in chondrosarcoma, compared to chordoma.</p><p><strong>Conclusion: </strong> As chordoma patients demonstrate a worse prognosis compared to chondrosarcoma patients, the differential expression of chordin, HOXA5 and ACAN and CD24 could be relevant for the pathophysiology of chordomas and may have diagnostic and treatment value. Further study on role of these genes in tumorigenesis is therefore warranted.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142846547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}